+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Cystinosis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Cystinosis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Diabetic Foot - Epidemiology Forecast to 2032 - Product Thumbnail Image

Diabetic Foot - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Diabetic Kidney Disease (DKD) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Diabetic Kidney Disease (DKD) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Type 1 Diabetes - Epidemiology Forecast - 2032 - Product Thumbnail Image

Type 1 Diabetes - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Vutrisiran - Epidemiology Forecast - 2032 - Product Thumbnail Image

Vutrisiran - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Endogenous Cushing's Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

Endogenous Cushing's Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Galactosemia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Galactosemia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Gaucher disease Type 1 - Epidemiology Forecast to 2032 - Product Thumbnail Image

Gaucher disease Type 1 - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Graves Orbitopathy - Epidemiology Forecast to 2032 - Product Thumbnail Image

Graves Orbitopathy - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Cardiac Amyloidosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Cardiac Amyloidosis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Batten Disease - Epidemiology Forecast - 2032 - Product Thumbnail Image

Batten Disease - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Hyperhidrosis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hyperhidrosis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Lactose Intolerance - Epidemiology Forecast to 2032 - Product Thumbnail Image

Lactose Intolerance - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Lipodystrophy Syndrome (LS) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Lipodystrophy Syndrome (LS) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Mucopolysaccharidosis I - Epidemiology Forecast to 2032 - Product Thumbnail Image

Mucopolysaccharidosis I - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Mucopolysaccharidosis II - Epidemiology Forecast to 2032 - Product Thumbnail Image

Mucopolysaccharidosis II - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Mucopolysaccharidosis III - Epidemiology Forecast to 2032 - Product Thumbnail Image

Mucopolysaccharidosis III - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Teriparatide- Biosimilar Insight, 2022 - Product Thumbnail Image

Teriparatide- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more